Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Outlook Therapeutics Inc OTLK

Healthcare Biotechnology
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and... see more

Current News (NDAQ:OTLK)

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

GlobeNewswire January 6, 2026

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) for the Treatment of Wet AMD

GlobeNewswire December 31, 2025

Outlook Therapeutics Announces New Employment Inducement Grants

GlobeNewswire December 26, 2025

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

GlobeNewswire December 19, 2025

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire November 24, 2025

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire November 13, 2025

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

GlobeNewswire November 3, 2025

Outlook Therapeutics Provides Update on Type A Meeting with FDA

GlobeNewswire September 29, 2025

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

GlobeNewswire September 3, 2025
View More News ››

Opinion & Analysis (NDAQ:OTLK)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:OTLK)

Buy buddy buy.

Otherwise FOMO
coolfooldumbguy - November 13, 2025

Back after 14 year hiatus

...
MISFIT1 - August 21, 2025

Using technical analysis for this stock.

It is signalling strength to the upside for shareholders today and so good luck to all of you
coolfooldumbguy - August 18, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK): Poised for Potenti

http://beyondspx.com/2024/08/01/outlook-therapeutics-inc-nasdaqotlk-poised-for-potential-approval-and-launch-in-europe-advancing-towards...
MikeTester - August 2, 2024

PDUFA TOMORROW

FDA to make its decision tomorrow, all aboard if its approved. Highish shorts already on board so let's see a short squeeze at the...
InvrsContrarian - August 28, 2023

Completes Patient Enrollment for ONS-5010/LYTENAVA™ Study

Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg) https://www...
schoolofrock - November 3, 2020
View more Bullboard ››

Playboy Inc.

Playboy Inc.

Playboy, Inc. operates as a pleasure and leisure company in the United States, Australia, China, the United Kingdom, and ...
View More »

Podcasts